MedTrace Logo

Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris

NCT01461655 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-03-10

Study results available
· View outcomes & findings →

Summary

The aim of this proof of principle study is to evaluate efficacy and safety of the sequential application of two marketed products for the treatment of acne vulgaris, using the Split-Face model

Conditions

  • Acne Vulgaris

Interventions

DRUG

marketed topical retinoid

once daily application, 4 weeks

DRUG

marketed topical NSAID

once daily application, 4 weeks

DRUG

vehicle gel

once daily application, 4 weeks

DRUG

marketed topical retinoid

once daily application, 4 weeks

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Catherine Mrs Queille-Roussel, MD · Centre de Pharmacologie Clinique Applique a la Dermatologie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-04-30
Completion
2012-05-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01461655 on ClinicalTrials.gov